New radiation technique aims to outsmart glioblastoma

NCT ID NCT07459101

Recruiting now Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to deliver radiation therapy for glioblastoma, a fast-growing brain tumor. Instead of treating a large area, doctors use MRI-guided adaptive radiation to focus more precisely on the tumor with reduced margins. The goal is to see if this approach can better control the tumor while causing fewer side effects. The trial will enroll 60 adults with newly diagnosed glioblastoma or grade 4 astrocytoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adaptive radiation therapy (dose painting with reduced margins)
What this could lead to: If successful, this could improve local tumor control and reduce side effects for glioblastoma patients, potentially extending survival.
What could go wrong: This is an early-phase study with only 60 participants, so results may not apply broadly. The approach may not improve outcomes and could still cause radiation-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, GRADE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA, GRADE IV GLIOBLASTOMA (GBM)

Contacts and locations

Locations

Sunnybrook Health Sciences Centre - Odette Cancer Centre
RECRUITING

Toronto, Ontario, M4N3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.